This trial will study the standard of care radiation therapy for squamous cell carcinoma of the head and neck, with the addition of either weekly or every 3-week cisplatin. The study will look at the relationship between the cisplatin toxicity and the level of reactive oxygen species generated by the drug.
1 Primary · 2 Secondary · Reporting Duration: 2 years
80 Total Participants · 2 Treatment Groups
Primary Treatment: Cisplatin · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: